Phenotypic Modulation of Cancer-Associated Antioxidant NQO1 Activity by Post-Translational Modifications and the Natural Diversity of the Human Genome
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Phosphorylation Acetylation Ubiquitination Intracellular degradation Ligand-dependent stability Cancer Neurological disorders
Fecha
2023-02-04Referencia bibliográfica
Pey, A.L. Phenotypic Modulation of Cancer-Associated Antioxidant NQO1 Activity by Post-Translational Modifications and the Natural Diversity of the Human Genome. Antioxidants 2023, 12, 379. [https://doi.org/10.3390/antiox12020379]
Patrocinador
ERDF/SpanishMinistry of Science, Innovation andUniversities—State Research Agency [Grant number RTI2018-096246-B-I00]; Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía [Grant number P18-RT-2413]; ERDF/Counseling of Economic transformation, Industry, Knowledge and Universities (Grant B-BIO-84-UGR20); Comunidad Valenciana (Grant number CIAICO/2021/135)Resumen
Human NAD(P)H:quinone oxidoreductase 1 (hNQO1) is a multifunctional and antioxidant
stress protein whose expression is controlled by the Nrf2 signaling pathway. hNQO1 dysregulation
is associated with cancer and neurological disorders. Recent works have shown that its activity
is also modulated by different post-translational modifications (PTMs), such as phosphorylation,
acetylation and ubiquitination, and these may synergize with naturally-occurring and inactivating
polymorphisms and mutations. Herein, I describe recent advances in the study of the effect of
PTMs and genetic variations on the structure and function of hNQO1 and their relationship with
disease development in different genetic backgrounds, as well as the physiological roles of these
modifications. I pay particular attention to the long-range allosteric effects exerted by PTMs and
natural variation on the multiple functions of hNQO1.